Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00412958
Status:
COMPLETED
Last Update Posted:
2014-12-17
First Post:
2006-12-18
Brief Title:
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment MIVI III
Sponsor:
ThromboGenics
Organization:
ThromboGenics
Study Overview
Official Title:
A Multicenter Randomized Placebo-Controlled Double-Masked Parallel Group Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy The MIVI III Microplasmin For Vitreous Injection III Trial
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None